证券代码：688273 证券简称：麦澜德 公告编号：2025-014 南京麦澜德医疗科技股份有限公司 关于 2024 年度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、计提资产减值准备情况概述 根据《企业会计准则》《上海证券交易所科创板股票上市规则》的相关规定, 为了更加真实、公允反映南京麦澜德医疗科技股份有限公司（以下简称"公司"） 截至 2024 年 12 月 31 日的资产及经营状况，基于谨慎性原则，公司对存在减值迹 象的相关资产计提相应的减值准备。经测算，2024 年度公司计提减值损失 11,177,430.18 元，具体情况如下: | 项目 | 计提减值金额（元） | 备注 | | --- | --- | --- | | 信用减值损失 | 1,358,803.05 | 含应收票据、应收账款、其他应收款减值 | | 资产减值损失 | 9,818,627.13 | 含商誉、固定资产、存货减值 | | 合计 | 11,177,430.18 | | 表日判断各项长期资产是否存在减值迹象，当存 ...

证券代码：688273 证券简称：麦澜德 公告编号：2025-005 南京麦澜德医疗科技股份有限公司 关于第二期以集中竞价交易方式回购公司股份的 进展公告 案之日起 12 个月内。具体内容详见公司于 2024 年 7 月 2 日在上海证券交易所网 站（www.sse.com.cn）披露的《关于以集中竞价交易方式回购股份的回购报告书》 （公告编号：2024-041）。 公司 2024 年半年度权益分派实施后，公司以集中竞价交易方式回购股份价格 上限由不超过人民币 32.00 元/股（含）调整为不超过人民币 31.61 元/股（含）。具 体内容详见公司于 2024 年 10 月 12 日在上海证券交易所网站（www.sse.com.cn） 披露的《关于 2024 年半年度权益分派实施后调整回购价格上限的公告》（公告编 号：2024-061）。 二、 回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司应在每个月的前 3 个交易日内公告截至上月 末的回购进展情况。现将公司回购股份进展的具体情况公告如下： 2025 年 3 月，公司通过上海证券交 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Viewpoints - The company is accelerating its expansion in women's health and actively laying out its brain-machine interface business [5] - The company focuses on pelvic floor rehabilitation and aims to meet the full lifecycle treatment needs of women [6] - The brain-machine interface market is projected to grow significantly, with a compound annual growth rate of 17.4% from 2025 to 2034 [7] - The company has made strategic investments in various health and beauty sectors, establishing a foundation for long-term growth [6][8] Summary by Relevant Sections Market Performance - The closing price of the company is 28.88 yuan, with a total market value of 2,888 million yuan and a circulating market value of 1,063.56 million yuan [3] Financial Forecast and Valuation - The company is expected to achieve revenues of 4.23 billion, 5.27 billion, and 6.69 billion yuan for the years 2024, 2025, and 2026, respectively, with year-on-year growth rates of 24.02%, 24.65%, and 27.01% [9][11] - The projected net profit attributable to the parent company for the same years is 1.02 billion, 1.30 billion, and 1.69 billion yuan, with growth rates of 13.75%, 27.51%, and 30.08% [9][11] - The current price-to-earnings ratio (PE) is projected to be 28, 22, and 17 for the years 2024, 2025, and 2026, respectively [9][11] Investment Logic - The company is well-positioned to benefit from the low penetration rate of pelvic floor and postpartum rehabilitation products in the domestic market [13] - The company is expanding into aesthetic medicine and sports rehabilitation, leveraging AI and brain-machine interface technologies for long-term revenue contributions [13] Key Assumptions - Revenue growth for pelvic floor and postpartum rehabilitation devices is expected to be 19.00%, 18.00%, and 18.00% from 2024 to 2026 [12] - Revenue growth for consumables and accessories is projected at 10.00%, 14.00%, and 18.50% for the same period [12] - The reproductive rehabilitation segment is anticipated to grow significantly, with expected growth rates of 74.60%, 55.00%, and 52.00% [12]

Group 1 - Chengdu Fusu Medical Technology Co., Ltd. has been established with a registered capital of 5 million yuan [1] - The legal representative of the company is Wang Yuran [1] - The business scope includes domestic cargo transportation agency, import and export agency, retail and wholesale of electronic components [1] Group 2 - The company is co-held by Mailand and others according to the equity penetration data [1]

证券代码：688273 证券简称：麦澜德 公告编号：2025-004 南京麦澜德医疗科技股份有限公司 关于第二期以集中竞价交易方式回购公司股份的 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/7/2，由控股股东杨瑞嘉先生和史志怀先生提议 | | --- | --- | | 回购方案实施期限 | 待第二届董事会第八次会议审议通过后 12 个月 | | 预计回购金额 | 2,000 万元~4,000 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 万股 103.00 | | 累计已回购股数占总股本比例 | 1.03% | | 累计已回购金额 | 2,002.1020 万元 | | 实际回购价格区间 | 18.57 元/股~19.99 元/股 | 一、 回购股份的基本情况 2024 年 6 月 24 日，南京麦澜德医疗科技股份有限公司（以下简称"公 ...

证券代码：688273 证券简称：麦澜德 公告编号：2025-003 南京麦澜德医疗科技股份有限公司 一、2024 年度主要财务数据和指标 2024 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载 2024 年度主要财务数据为初步核算数据，未经会计师事务所审计， 具体数据以南京麦澜德医疗科技股份有限公司（以下简称"公司"）2024 年年度报 告为准，提请投资者注意投资风险。 三、风险提示 单位：万元 本公告所载 2024 年度主要财务数据为初步核算数据，未经会计师事务所审计， 具体数据以公司正式披露的经审计后的 2024 年年度报告为准，敬请广大投资者注 意投资风险。 | 项目 | 本报告期 | 上年同期 | 增减变动幅度（％） | | --- | --- | --- | --- | | 营业总收入 | 42,268.01 | 34,082.47 | 24.02 | | 营业利润 | 11,278.90 | 10,248.41 | 10.06 | | 利润总额 | 12,346.36 | 10 ...

证券代码：688273 证券简称：麦澜德 公告编号：2025-002 南京麦澜德医疗科技股份有限公司 关于第二期以集中竞价交易方式回购公司股份的 案之日起 12 个月内。具体内容详见公司于 2024 年 7 月 2 日在上海证券交易所网 站（www.sse.com.cm）披露的《关于以集中竞价交易方式回购股份的回购报告书》 （公告编号：2024-041）。 公司 2024 年半年度权益分派实施后，公司以集中竞价交易方式回购股份价格 上限由不超过人民币 32.00 元/股（含）调整为不超过人民币 31.61 元/股（含）。具 体内容详见公司于 2024 年 10 月 12 日在上海证券交易所网站（www.sse.com.cm） 披露的《关于 2024 年半年度权益分派实施后调整回购价格上限的公告》（公告编 号：2024-061）。 二、 回购股份的进展情况 进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/7/2，由控股股东杨瑞嘉先生和史志怀先生提议 | | -- ...

南京证券股份有限公司 关于南京麦澜德医疗科技股份有限公司 2024年度持续督导工作现场检查报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市规 则》《上海证券交易所科创板上市公司自律监管指引第1号——规范运作》等有关法 律、法规的规定，南京证券股份有限公司（以下简称"保荐机构"或"南京证券"）作 为正在履行南京麦澜德医疗科技股份有限公司（以下简称"麦澜德"或"公司"）持续 督导工作的保荐机构，对公司2024年1月1日至本次现场检查期间（以下简称"本持续 督导期间"）的规范运作情况进行了现场检查，现就现场检查的有关情况报告如下： 一、本次现场检查的基本情况 2024年12月25日至2024年12月30日 （四）现场检查人员 张红、刘姝含、操函希 （五）现场检查内容 公司治理和内部控制情况、信息披露情况、公司的独立性以及与控股股东、实 际控制人及其他关联方资金往来情况、募集资金使用情况、关联交易、对外担保、 重大对外投资情况、公司经营状况等。 （六）现场检查手段 （一）保荐机构 南京证券股份有限公司 （二）保荐代表人 李建勤、张红 （三）现场检查时间 1、与公司部分董事、高级管理人员进行访谈 ...

Group 1: Company Overview and Strategy - Nanjing Maillande Medical Technology Co., Ltd. focuses on the promotion of the "Magnetic Electric Thermal Imaging · Smart Integration PI-ONE" pelvic floor intelligent diagnosis and treatment system, enhancing market competitiveness and establishing a solid industry moat [2][3] - The company collaborates with the National Health Commission's research institute to promote national projects, leveraging academic channels for expansion [3] - The new product rollout is planned and executed in phases, aligning with market feedback and company expectations [3] Group 2: Product Applications and Market Insights - The reproductive anti-aging products are widely used in medical beauty institutions and reproductive centers, with a direct sales model supplemented by distribution [4] - The market for reproductive health is in the introduction and growth stages, driven by increasing awareness and demand among women for reproductive health services [4][5] - The electric ultrasound therapy device targets populations with reproductive function decline, while the uterine recovery device is aimed at postpartum and post-abortion fertility preservation [4] Group 3: Financial Performance and Market Challenges - Approximately 85% of the company's business comes from the hospital sector, with external market performance affected by declining birth rates, although business volume has stabilized in recent years [5] - The aging population and rising health awareness are contributing to an increasing number of women seeking screening and treatment for pelvic floor dysfunction (PFD) [5] Group 4: Future Directions and Risk Management - The company maintains a strategy of "internal growth and external mergers," actively seeking new project opportunities that align with its strategic direction [4] - Caution is exercised in evaluating market conditions, project risks, and potential returns before pursuing investments and acquisitions [4][6] - Investors are advised to be aware of the risks associated with industry forecasts and company development strategies, as these do not constitute commitments from the company [6]

Group 1: Financial Performance - In the first three quarters of 2024, the company achieved a revenue of approximately 330 million CNY, representing a year-on-year growth of 13.81% [2] - The net profit attributable to the parent company was approximately 96.07 million CNY, with a year-on-year increase of 13.37% [3] Group 2: Business Development Directions - The future business development and growth logic are primarily driven by three segments: pelvic floor rehabilitation, reproductive anti-aging, and rehabilitation [3] - The pelvic floor segment is experiencing increasing demand due to the aging population and rising health awareness, with a growing number of women actively screening and treating pelvic floor dysfunction [3] - The reproductive anti-aging segment has formed an integrated ecosystem since the launch of its first product in 2022, generating over 50 million CNY in revenue in the first half of 2024 [4] Group 3: Product Innovations - The company launched the "Magnetic-Electric Thermal Imaging · Smart Integration PI-ONE" system in the first quarter, which includes three new products for pelvic floor rehabilitation [6] - The new pelvic floor rehabilitation products aim to provide a comprehensive solution, integrating various technologies for personalized treatment plans [7] Group 4: Market Strategy - The company plans to continue focusing on women's health and beauty, actively expanding into new technologies, products, markets, and business areas [5] - Despite a slowdown in the overall growth of the pelvic floor rehabilitation industry, the company has maintained a relatively stable growth rate compared to peers, indicating a strong market position [5] Group 5: Revenue Composition - Revenue from consumables accounts for approximately 25% of total revenue, with a stable gross margin [7]